Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,955Revenue (TTM) $M1.3Net Margin (%)-19,049.6Altman Z-Score6.3
Enterprise Value $M1,834EPS (TTM) $-5.4Operating Margin %-18,995.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-19,049.6Higher ROA y-yN
Price/Book15.910-y EBITDA Growth Rate %2.4Quick Ratio2.3Cash flow > EarningsY
Price/Sales1,3485-y EBITDA Growth Rate %36.1Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-161.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M47.9ROIC % (ttm)-786.8Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 40.81142%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 40.8181%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 40.8129%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 40.8161%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 40.8138%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 40.816%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 40.8142%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 40.8153%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 40.81527%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 40.81723%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 40.81419%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 40.81321%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-18.51view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-31.98view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-31.98view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-31.98view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-18.38view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-18.38view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-18.38view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$3036.03view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.28150.68view
Barry RichardDirector 2016-03-14Buy75,000$15.66160.6view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Why Sarepta is Sinking Oct 27 2016
Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT Oct 27 2016
Sarepta Therapeutics reports 3Q loss Oct 27 2016
Sarepta Therapeutics reports 3Q loss Oct 27 2016
Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Oct 27 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 27 2016
7:11 am Sarepta Therapeutics beats by $0.33 Oct 27 2016
Q3 2016 Sarepta Therapeutics Inc Earnings Release - Before Market Open Oct 27 2016
Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate... Oct 27 2016
Coverage initiated on Sarepta Therapeutics by Morgan Stanley Oct 27 2016
Sarepta: 'Setting Aside the Controversy Around the Questionable Data…' Oct 25 2016
Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate... Oct 25 2016
Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate... Oct 24 2016
Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry Oct 21 2016
Trader Be Nimble, Trader Be Quick Oct 20 2016
Sarepta Muscular Dystrophy Drug Interrupts 5-Day Biotech Slump Oct 18 2016
Sarepta Therapeutics: If You Approve It They Will Come Oct 18 2016
PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal Oct 18 2016
Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics Oct 13 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)